« Zurück
Home /
Abemaciclib (methanesulfonate)

Abemaciclib (methanesulfonate)

ArtNr	HY-16297-500mg
Hersteller	MedChem Express
CAS-Nr.	1231930-82-7
Menge	500 mg
Quantity options	100 mg 10mM/1mL 10 mg 200 mg 500 mg 50 mg 5 mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Head & Neck Cancer Brain Cancer
Typ	Inhibitors
Clon	N/A
Specific against	other
Purity	99.95
Formula	C28H36F2N8O3S
Citations	Biochem Biophys Rep. 27, September 2021, 101099<br/>Biochem Biophys Res Commun. 2018 Sep 26;504(1):231-237. <br/>Biochem Pharmacol. 2017 Jan 15;124:29-42.<br/>Biochim Biophys Acta. 2017 Nov 20;1865(2):354-363.<br/>bioRxiv. 2020 Jun.<br/>Cancer Res. 2016 Nov 15;76(22):6723-6734. <br/>Cancer Res. 2023 Jun 29;CAN-23-0705.<br/>Cell Death Dis. 2019 Mar 20;10(4):271.<br/>Cell Rep. 2017 Oct 31;21(5):1386-1398.<br/>Cell Rep. 2022 Sep 13;40(11):111331.<br/>Cell. 2018 Nov 1;175(4):984-997.e24.<br/>Clin Cancer Res. 2024 May 8.<br/>EMBO J. 2022 Jan 5;e108946.<br/>Harvard Medical School LINCS LIBRARY<br/>J Exp Clin Cancer Res. 2022 Apr 21;41(1):149.<br/>J Oncol. 2019 Jun 2;2019:5952836. <br/>Mol Cell. 2017 Oct 19;68(2):336-349.e6.<br/>Mol Oncol. 2017 Aug;11(8):1035-1049.<br/>Nat Commun. 2017 Jun 27;8:15916.<br/>Nat Commun. 2019 Jun 28;10(1):2860.<br/>Nature. 2017 Aug 24;548(7668):471-475. <br/>Nutrition. 2019 Apr;60:217-226. <br/>Oncotarget. 2017 Jul 27;8(56):95116-95134. <br/>Oncotarget. 2017 Jun 27;8(40):67422-67438. <br/>Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.<br/>STAR Protocols. 2020 Jun 3;1(1):100024.<br/>ACS Appl Mater Interfaces. 2022 May 11;14(18):20628-20640.<br/>Adv Funct Mater. 2021 Apr 30.<br/>Adv Sci (Weinh). 2020 Aug 4;7(18):2000906.<br/>Adv Sci (Weinh). 2022 Aug 2;e2201834.<br/>Bioact Mater. 8 September 2021.<br/>Biochem Biophys Res Commun. 20 December 2021.<br/>Biomed Chromatogr. 2020 Jun;34(6):e4825.<br/>bioRxiv. 2023 Jan 25.<br/>bioRxiv. 2023 Jul 17.<br/>bioRxiv. 2023 Jul 19.<br/>Blood Cancer J. 2022 Jan 11;12(1):5.<br/>Br J Cancer. 2022 Jan 14.<br/>Breast Cancer Res. 2019 Dec 26;21(1):150.<br/>Cancer Discov. 2023 Dec 4.<br/>Cancer Res. 2017 May 1;77(9):2488-2499.<br/>Cancer Res. 2019 Oct 15;79(20):5245-5259.<br/>Cancer Res. 2022 May 16;82(10):1890-1908.<br/>Cell Chem Biol. 2019 Aug 15;26(8):1067-1080.e8. <br/>Cell Death Dis. 2020 Oct 28;11(10):925.<br/>Cell Rep. 2022 Dec 20;41(12):111826.<br/>Cell. 2023 Jun 8;186(12):2628-2643.e21.<br/>Commun Biol. 2021 Mar 25;4(1):399.<br/>Department of Biochemistry. 2020 Oct.<br/>Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.<br/>Front Oncol. 2021 Jul 13;11:704042.<br/>Fundam Clin Pharmacol. 2021 Feb 1.<br/>Heliyon. 2023 Sep 13.<br/>Int J Biol Sci. 2019 Jan 1;15(3):522-532. <br/>Int J Mol Sci. 2021 Jan 8;22(2):E575.<br/>Int J Mol Sci. 2022 Feb 24;23(5):2493.<br/>J Cell Biochem. 2023 Aug 11.<br/>J Med Chem. 2023 Mar 6.<br/>J Oncol. 2022 Jun 23;2022:8724933.<br/>JCI Insight. 2021 Dec 21;e154402.<br/>Leuk Res. September 2022, 106920.<br/>Nat Commun. 2021 Aug 25;12(1):5112.<br/>Nat Commun. 2021 Nov 16;12(1):6607.<br/>Nat Commun. 2022 Aug 10;13(1):4689.<br/>Nat Metab. 2020 Jan;2(1):41-49.<br/>Nature Cancer. 2021 Apr;2(4):429-443.<br/>Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 4.<br/>NPJ Precis Oncol. 2021 Mar 19;5(1):20.<br/>Patent. US20200108066A1<br/>R Soc Open Sci. 2019 Jan 23;6(1):181714.<br/>Sci Rep. 2022 Jul 20;12(1):12420.<br/>Sci Rep. 2024 May 8;14(1):10582.<br/>Sci Rep. 2019 Oct 22;9(1):15099. <br/>SSRN. 2022 Nov 21.<br/>SSRN. 2023 Sep 29.<br/>Transl Lung Cancer Res. 2024 May 31;13(5):1032-1046.<br/>University of Gothenburg. 2023 Jun 27.<br/>[1]Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget. 2016 Mar 22;7(12):14803-13.<br/>[2]Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63.<br/>[3]Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32(5):825-37.<br/>[4]Wu T, et al. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Biochem Pharmacol. 2017 Jan 15;124:29-42.
Smiles	CC(N1C2=CC(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)=CC(F)=C2N=C1C)C.CS(=O)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY2835219 (methanesulfonate)
Lieferbar
Product Description	Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively[1][2][3].
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	602.70
Clinical Information	Launched
Manufacturers Research Area	Cancer
Solubility	DMSO : 10 mg/mL (ultrasonic; warming; heat to 80°C)\|H2O : 125 mg/mL (ultrasonic)
Target	CDK
Manufacturers Target	CDK
Isoform	CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9
Manufacturers Pathway	Cell Cycle/DNA Damage
Manufacturers Product type	Reference compound

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-16297-500mg-safety-datasheet.pdf